AB0799 The Efficacy of Platelet Rich Plasma Injection on Pain Severity and Functional Status in Patients with Knee Osteoarthritis

Background Knee osteoarthritis is one of the most frequent causes of pain and disability (1). The aims of the treatment are to control pain, prevent or improve joint functions, facilitate functional self-dependence and increase quality of life (2). Platelet Rich Plasma (PRP) injection is one of the current treatment options which has been used with increasing frequency. The PRP is obtained from autolog blood that contains intensive platelets and growth factors 3-5 times more than normal plasma and contributes tissue healing. Objectives The aim of this study is to investigate the efficacy of PRP injection on pain severity and function in knee osteoarthritis. Methods 515 patients (1030 knees) with knee osteoarthritis according to ACR criterias were included in the study. The data of the patients who underwent PRP injections 2 times within 3 months was investigated retrospectively. Pain severity and functional status were assessed with VAS and WOMAC questionnaire before and after the treatment. Results Before the treatment, the mean values of VAS in motion and rest were 7,37±2,03 and 4,11±2,47; respectively. After the treatment the mean values of VAS were 5,35±2,26 and 2,25±2,15. WOMAC total scores were 80,93±17,32 and 61,75±18,15 before and after the treatment. Statistically significant differences were found in VAS and WOMAC scores before and after the treatment (p=0.000). Conclusions In this study, the efficacy of PRP injection on pain severity and functional status in knee osteoarthritis was demonstrated however it is clear that high quality randomised plasebo controlled studies are needed. References Hunter DJ, Log GH. The management of osteoarthritis: an overview and call to appropriate conservative treatment Rheum Dis Clin N Am 2008;34:689-712 Evidence-Based Recommendations for the Management of Knee Osteoarthritis: A Consensus Report of the Turkish League Against Rheumatism Turk J Rheumatol 2012;27(1):1-17 Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5127